Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...

Moderna's updated mRNA COVID-19 vaccine has been approved in major markets worldwide. In the U.S., the Company was ready for an earlier COVID vaccine approval compared to the prior season ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. Vandana Singh Benzinga Bulls And ...